skip to main content

Tamoxifen Endometrial Risk — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerTamoxifen Endometrial RiskSCE Medical Oncology

A postmenopausal patient taking tamoxifen reports new vaginal bleeding. Transvaginal ultrasound shows a heterogeneous 12 mm endometrium. Which investigation plan best accounts for the effect of tamoxifen on ultrasound interpretation?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Refer urgently for hysteroscopy with endometrial biopsy rather than relying on the thickness threshold

Tamoxifen distorts endometrial architecture, so ultrasound thickness thresholds are unreliable in a symptomatic patient. Current NHS guidance advises hysteroscopy with endometrial biopsy for postmenopausal bleeding during tamoxifen use. Waiting for a further thickness increase can delay cancer diagnosis. Blind sampling alone may miss focal pathology and should not replace the tamoxifen-specific hysteroscopic assessment. MRI stages known disease rather than replacing initial tissue diagnosis. Stopping tamoxifen does not remove the need to investigate postmenopausal bleeding.

Reference: NHS Greater Glasgow and Clyde postmenopausal-bleeding guideline (Updated 2025; current NHS guidance): https://www.rightdecisions.scot.nhs.uk/ggc-clinical-guidelines/gynaecology/gynaecology-guidelines/guidelines-a-z-all-gynaecology-guidelines/postmenopausal-bleeding-486/